SCHEMBL1949495

SCHEMBL1949495

CC(C)(C)OC(=O)N1C2CCCC1CC(Oc1ccc3ccc(=O)oc3c1)C2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.47
KDM4E B2RXH2 7/20 0.45
ALDH1A1 P00352 5/20 0.45
GLA P06280 4/20 0.45
GAA P10253 4/20 0.45
KMT2A Q03164 1/20 0.45
HPGD P15428 3/20 0.45
MAPT P10636 2/20 0.45
HIF1A Q16665 1/20 0.45
CA12 O43570 3/20 0.43
CA9 Q16790 3/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
HSD17B10 Q99714 2/20 0.42
TSHR P16473 1/20 0.42
CA1 P00915 2/20 0.41
HRH3 Q9Y5N1 1/20 0.41
CA3 P07451 1/20 0.41
AKR1B1 P15121 1/20 0.41
CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1949494 1.00 MAOA (0.47) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL1011111 0.96 MAOA (0.47) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL1091721 0.89 CA12 (0.46) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL4438932 0.88 KDM4E (0.42) MAOAKDM4EALDH1A1GLAGAA
SCHEMBL1949225 0.87 MAOB (0.45) MAOAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL1949223 0.87 MAOB (0.45) MAOAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL741084 0.83 SLC6A2 (0.48) MAOAALDH1A1HPGDHSD17B10MAOB
SCHEMBL741083 0.83 SLC6A2 (0.48) MAOAALDH1A1HPGDHSD17B10MAOB
SCHEMBL15304583 0.83 SLC6A2 (0.48) MAOAALDH1A1HPGDHSD17B10MAOB
SCHEMBL3183936 0.82 MAOB (0.44) MAOAKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110136854-A1 NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2011-06-09 US disclosed
EP-2242754-A1 NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NeuroSearch A/S (DK) 2010-10-27 EP disclosed
WO-2009098209-A1 NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136854-A1 NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC6A2, SLC18A3 MAOA 5/4885KDM4E 225/4885ALDH1A1 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.